Open Access

Evaluation of skin sensitization based on interleukin‑2 promoter activation in Jurkat cells

  • Authors:
    • Taichi Nagahata
    • Yoshio Tsujino
    • Eiji Takayama
    • Haruka Hikasa
    • Ayano Satoh
  • View Affiliations

  • Published online on: November 8, 2021     https://doi.org/10.3892/br.2021.1486
  • Article Number: 3
  • Copyright: © Nagahata et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Skin sensitization is an allergic reaction caused by certain chemical substances, and is an important factor to be taken into consideration when evaluating the safety of numerous types of products. Although animal testing has long been used to evaluate skin sensitization, the recent trend to regulate such testing has led to the development and use of alternative methods. Skin sensitization reactions are summarized in the form of an adverse outcome pathway consisting of four key events (KE), including covalent binding to skin proteins (KE1), keratinocyte activation (KE2), and dendritic cell activation (KE3). Equivalent alternative methods have been developed for KE1 to KE3, but no valid alternative has yet been developed for the evaluation of KE4 and T‑cell activation. Current alternative methods rely on data from KE1 to KE3 to predict the effect of chemicals on skin sensitization. The addition of KE4 data is expected to improve the accuracy and reproducibility of such predictions. The aim of this study was to establish an assay to evaluate KE4 T‑cell activation to supplement data on skin sensitization related to KE4. To evaluate T‑cell activation, the Jurkat T‑cell line stably expressing luciferase downstream of the pro‑inflammatory cytokine interleukin‑2 promoter was used. After exposure to known skin sensitizing agents and control substances, luciferase activity measurements revealed that this assay was valid for evaluating skin sensitization. However, two skin sensitizers known to have immunosuppressive effects on T‑cells reacted negatively in this assay. The results revealed that this assay simultaneously allows for monitoring of the skin sensitization and immuno‑suppressiveness of chemical substances and supplements KE4 T‑cell activation data, and may thus contribute to reducing the use of animal experiments.
View Figures
View References

Related Articles

Journal Cover

January-2022
Volume 16 Issue 1

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Nagahata T, Tsujino Y, Takayama E, Hikasa H and Satoh A: Evaluation of skin sensitization based on interleukin‑2 promoter activation in Jurkat cells. Biomed Rep 16: 3, 2022
APA
Nagahata, T., Tsujino, Y., Takayama, E., Hikasa, H., & Satoh, A. (2022). Evaluation of skin sensitization based on interleukin‑2 promoter activation in Jurkat cells. Biomedical Reports, 16, 3. https://doi.org/10.3892/br.2021.1486
MLA
Nagahata, T., Tsujino, Y., Takayama, E., Hikasa, H., Satoh, A."Evaluation of skin sensitization based on interleukin‑2 promoter activation in Jurkat cells". Biomedical Reports 16.1 (2022): 3.
Chicago
Nagahata, T., Tsujino, Y., Takayama, E., Hikasa, H., Satoh, A."Evaluation of skin sensitization based on interleukin‑2 promoter activation in Jurkat cells". Biomedical Reports 16, no. 1 (2022): 3. https://doi.org/10.3892/br.2021.1486